AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

May 24, 2017

AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., May 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Tuesday, June 13, 2017. Bill Chase, executive vice president and chief financial officer, will present at 10 a.m. Central time.

May 19, 2017

AbbVie to Present at the Jefferies 2017 Global Healthcare Conference

NORTH CHICAGO, Ill., May 19, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017. Bill Chase, executive vice president and chief financial officer, will present at 1:30 p.m. Central time.

May 17, 2017

AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting

NORTH CHICAGO, Ill., May 17, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data about the company's portfolio of approved and investigational oncology medicines during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2-6, in Chicago. A total of 23 abstracts have been accepted across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors.

May 17, 2017

AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis

NORTH CHICAGO, Ill., May 17, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data from two replicate Phase 3 studies evaluating the efficacy and safety of elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, in premenopausal women with endometriosis, will be presented at the 13th World Congress on Endometriosis in Vancouver, Canada.  New data highlighting the effects of two different elagolix doses and dosing regimens on ovarian sex hormones and ovulation will also be presented.

May 14, 2017

IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NORTH CHICAGO, Ill., May 14, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results from an analysis of data pooled from three Phase 3 studies evaluating IMBRUVICA® (ibrutinib) use in patients with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): RESONATETM, RESONATETM-2 and HELIOS. In this analysis, CLL/SLL patients with genomic abnormalities that typically put them at high risk for poor outcomes achieved higher complete response (CR) rates and overall response rates (ORR), as well as longer progression free survival (PFS) at 24 months and overall survival (OS) at 30 months, when treated with IMBRUVICA versus comparator-treated patients. In RESONATE, patients received IMBRUVICA or ofatumumab; in RESONATE-2, patients received IMBRUVICA or chlorambucil; and in HELIOS, patients received IMBRUVICA plus bendamustine and rituximab (BR) or placebo plus BR. The high-risk genomic abnormalities reviewed were deletion 11q (del 11q), trisomy 12, complex karyotype (CK) and unmutated immunoglobulin heavy-chain variable-region (IGHV). In IMBRUVICA-treated patients, the presence of del 11q was associated with trends of longer PFS and OS than patients without del 11q when treated with IMBRUVICA (abstract #19). These data will be presented today in an oral presentation at the 17th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York, NY.

May 09, 2017

AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease

NORTH CHICAGO, Ill., May 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced promising results from CELEST, a Phase 2, randomized, double-blind, placebo-controlled study evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in adult patients with moderately to severely active Crohn's disease. These data are being presented today during the Clinical Science: Late-Breaking Abstract Plenary Session (Presentation #874h) at Digestive Disease Week® 2017.

May 05, 2017

AbbVie to Present at the UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 5, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Monday, May 22, 2017. Richard A. Gonzalez, chairman of the board and chief executive officer, will present at 7 a.m. Central time.

May 04, 2017

AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week®

NORTH CHICAGO, Ill., May 4, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data from 20 abstracts in gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW) 2017, May 6 – 9, in Chicago.

Apr 27, 2017

AbbVie Reports First-Quarter 2017 Financial Results

NORTH CHICAGO, Ill., April 27, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2017.

Apr 21, 2017

AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference

NORTH CHICAGO, Ill., April 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017. William Chase, executive vice president and chief financial officer, will present at 7:40 a.m. Central time.